Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 1
1993 1
1994 1
1995 2
1998 3
2000 2
2001 1
2002 1
2003 1
2004 1
2005 5
2006 2
2007 1
2009 1
2010 2
2011 1
2013 1
2014 2
2016 1
2017 4
2018 5
2019 7
2020 2
2021 2
2022 2
2023 2
2024 3
2025 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

60 results

Results by year

Filters applied: . Clear all
Page 1
Radical Reactions of Ynamides.
Tan TD, Wang ZS, Qian PC, Ye LW. Tan TD, et al. Small Methods. 2021 Mar;5(3):e2000673. doi: 10.1002/smtd.202000673. Epub 2020 Sep 29. Small Methods. 2021. PMID: 34927818 Review.
Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial.
Kim WS, Kim TM, Cho SG, Jarque I, Iskierka-Jażdżewska E, Poon LM, Prince HM, Zhang H, Cao J, Zhang M, Tessoulin B, Oh SY, Lim F, Carpio C, Tan TD, Ayyappan S, Gutierrez A, Cai J, Ufkin M, Shariff S, Brouwer-Visser J, Chaudhry A, Mohamed H, Ambati S, Walewski J; ELM-2 Investigators. Kim WS, et al. Among authors: tan td. Nat Cancer. 2025 Mar;6(3):528-539. doi: 10.1038/s43018-025-00921-6. Epub 2025 Mar 17. Nat Cancer. 2025. PMID: 40097657 Free PMC article. Clinical Trial.
Author Correction: Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial.
Kim WS, Kim TM, Cho SG, Jarque I, Iskierka-Jażdżewska E, Poon LM, Prince HM, Zhang H, Cao J, Zhang M, Tessoulin B, Oh SY, Lim F, Carpio C, Tan TD, Ayyappan S, Gutierrez A, Cai J, Ufkin M, Shariff S, Brouwer-Visser J, Chaudhry A, Mohamed H, Ambati S, Walewski J; ELM-2 Investigators. Kim WS, et al. Among authors: tan td. Nat Cancer. 2025 May;6(5):907. doi: 10.1038/s43018-025-00967-6. Nat Cancer. 2025. PMID: 40240622 Free PMC article. No abstract available.
Ten-year epidemiology and risk factors of cytomegalovirus infection in hematopoietic stem cell transplantation patients in Taiwan.
Huang YC, Hsiao FY, Guan ST, Yao M, Liu CJ, Chen TT, Lin TL, Liu YC, Chen TY, Hong YC, Ma MC, Tan TD, Wang CC, Wu YY, Liao PW, Wu YF, Chen YY, Yu YB, Hsieh YY, Lee MY, Liu JH, Lin SW, Ko BS. Huang YC, et al. Among authors: tan td. J Microbiol Immunol Infect. 2024 Jun;57(3):365-374. doi: 10.1016/j.jmii.2024.02.005. Epub 2024 Mar 6. J Microbiol Immunol Infect. 2024. PMID: 38503632 Free article.
Stem cell transplant for mantle cell lymphoma in Taiwan.
Wang YH, Hsieh CY, Hsiao LT, Lin TL, Liu YC, Yao M, Tan TD, Ko BS. Wang YH, et al. Among authors: tan td. Sci Rep. 2022 Apr 5;12(1):5662. doi: 10.1038/s41598-022-09539-5. Sci Rep. 2022. PMID: 35383213 Free PMC article.
60 results